Clinical Trial Update: Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections [Phase 3]

View source ↗

Summary

Phase 3 trial is recruiting to assess efficacy and safety of meropenem plus pralubactam for carbapenem-resistant Enterobacteriaceae infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bloodstream Infection
• Complicated Intra-abdominal Infection
• Complicated Urinary Tract Infection
• Hospital-acquired Bacterial Pneumonia
• Ventilator-associated Bacterial Pneumonia

Drugs mentioned

• Meropenem (Meropenem)
• Pralubactam (pralubactam)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP) | Phase 3 | Status: RECRUITING